拉米夫定与肝毒净联合对慢性乙型肝炎病毒标志物的影响  

Effect of lamivudine and Gandujing combination therapy on patients with HBV infection

作　　者：魏晓霞[1] 陈凤英[1] 

机构地区：[1]河南省人民医院,郑州450003

出　　处：《中国卫生检验杂志》2008年第8期1589-1590,共2页Chinese Journal of Health Laboratory Technology

摘　　要：目的:应用拉米夫定与肝毒净联合治疗慢性乙型肝炎,观察HBV标志物及HBV-DNA、ALT等指标。方法:联合治疗组用拉米夫定100 mg口服,每日1次,疗程12月,初始3个月同时给予肝毒净每次3粒,每日3次,对照组仅用拉米夫定100 mg口服,每日1次,疗程12月。结果:联合治疗组患者血清HBeAg阴转率、HBeAg抗HBe血清转换率明显高于对照组。结论:拉米夫定联合肝毒净治疗慢性乙型肝炎具有一定的临床应用价值。Objective： To investigate the changes of HBV-signs, HBV-DNA and ALT during Lamivudine and Gandujing combination therapy on patients with chronic hepatitis B.Methods：Combined application group：Lmivudine（100 mg/oral/qd/12 months） and Gandujing（3 capsules/oral/tid/for the first 3 months）.Control group： Lamivudine only（100 mg/oral/qd/12 months）.Results：The portion of HBeAg reduction and HBeAg seroconversion in combined application group were significantly greater than those in control group.Conclusion：It is clinically useful for Lamivudine and Gandujing combination therapy on patients with chronic hepatitis B.

关 键 词：肝炎 乙型 慢性 肝毒净 拉米夫定 

分 类 号：R512.6[医药卫生—内科学]